Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

Anterior Uveitis Clinical Trial

Official title:
A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.

Clinical Trial Description

Anterior uveitis is a disorder of the eye associated with intraocular inflammation of the anterior portion of the uvea, particularly the iris and/or ciliary body. It is distinct from other iterations of uveitis such as posterior, diffuse and intermediate uveitis although it is the most common form of uveitis and accounts for approximately 75% of cases.

In a Phase 1/2 study (EGP-437-001), the delivery of EGP-437 (40 mg/mL dexamethasone phosphate solution) at four different iontophoresis dose levels was studied in 40 subjects with non-infectious anterior segment uveitis. The study demonstrated that a single EGP-437 treatment: lowered anterior chamber cell (ACC) scores in the majority of patients without requiring additional treatment; produced low short-term systemic exposure to dexamethasone and dexamethasone phosphate; and produced the most beneficial effects in the 1.6 and 4.8 mA-min dose groups; and caused mainly minor AEs and no non-ocular systemic corticosteroid mediated effects were observed.

The Phase 3 study is intended to confirm and extend the results from the Phase 2 study. The study is designed to assess the safety and efficacy Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA and accompanying placebo eyedrops in comparison to Ocular Iontophoresis with sodium citrate buffer solution 4.0 mA-min at 1.5 mA and accompanying prednisolone acetate (1%) eyedrops for the treatment of non-infectious anterior segment uveitis. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01505088
Study type	Interventional
Source	Eyegate Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	December 2011
Completion date	March 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00476593` - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications	N/A
Recruiting	`NCT01486693` - Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis	N/A
Recruiting	`NCT01156285` - Acute Anterior Uveitis: Psychic Burden and Pain	N/A
Terminated	`NCT00333996` - A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis	Phase 2/Phase 3
Completed	`NCT00405496` - Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis	Phase 2
Completed	`NCT02764697` - Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients	Phase 4
Completed	`NCT01376362` - Topical Interferon Gamma for Macular Edema Secondary to Uveitis	Phase 1/Phase 2
Recruiting	`NCT00407316` - Quality of Life and Visual Function in Uveitis Patients	Phase 0
Completed	`NCT02725177` - Ocular Sarcoidosis Open Label Trial of ACTHAR Gel	N/A
Completed	`NCT01647529` - Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis	N/A
Completed	`NCT00823173` - Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis	Phase 2
Completed	`NCT02517619` - Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis	Phase 3
Completed	`NCT02879084` - Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis
Completed	`NCT02765308` - Aqueous Humor Dynamics and Hypertensive Uveitis	N/A
Completed	`NCT01154010` - PEMF: an Adjunct Therapy for Anterior Uveitis	N/A
Completed	`NCT00130637` - Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis	Phase 2
Completed	`NCT00406887` - Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis	Phase 3
Completed	`NCT00876434` - Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.